Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -14,858 | -11,681 | -6,076 | -3,545 | -18,851 |
| Depreciation Amortization | 3 | 2 | 2 | 1 | 4 |
| Accounts payable and accrued liabilities | -3,634 | -1,806 | 808 | 46 | 1,322 |
| Other Working Capital | -3,694 | -1,269 | 794 | 149 | 3,699 |
| Other Operating Activity | 5,069 | 3,112 | -371 | 157 | -314 |
| Operating Cash Flow | $-17,113 | $-11,642 | $-4,843 | $-3,192 | $-14,140 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -4 | N/A | N/A | N/A | -4 |
| Investing Cash Flow | $-4 | $N/A | $N/A | $N/A | $-4 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 23,398 | 18,393 | 5,980 | 3,546 | 5,279 |
| Other Financing Activity | -368 | -326 | -194 | -88 | -642 |
| Financing Cash Flow | $23,030 | $18,067 | $5,785 | $3,459 | $4,637 |
| Beginning Cash Position | 549 | 549 | 549 | 549 | 10,055 |
| End Cash Position | 6,461 | 6,973 | 1,492 | 815 | 549 |
| Net Cash Flow | $5,913 | $6,424 | $943 | $267 | $-9,507 |
| Free Cash Flow | |||||
| Operating Cash Flow | -17,113 | -11,642 | -4,843 | -3,192 | -14,140 |
| Capital Expenditure | -4 | N/A | N/A | N/A | -4 |
| Free Cash Flow | -17,118 | -11,642 | -4,843 | -3,192 | -14,144 |